William Strickland
Family Medicine · Cayce, SCNPI 1013321546
Payments from drug & device makers
Across 378 payments — averaging $15.96 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$1K
- Lilly USA, LLC$814
- AstraZeneca$701
- AbbVie$513
- Pfizer$432
- GSK$291
- plus $2K from 26 others
What the payments were for
- Food & beverage$6,021100%
- Education$120%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 58 | $1,017 |
| Lilly USA, LLC | 58 | $814 |
| AstraZeneca(2 entities) | 44 | $701 |
| AbbVie | 36 | $513 |
| Pfizer | 29 | $432 |
| GSK | 18 | $291 |
| Amgen | 17 | $261 |
| Novartis | 11 | $203 |
| Exact Sciences | 10 | $171 |
| Abbott | 10 | $169 |
| Merck | 11 | $160 |
| Dexcom, Inc. | 5 | $154 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 8 | $134 |
| Amarin Pharma, Inc. | 8 | $121 |
| Bayer | 7 | $110 |
| Sanofi-aventis U.S. LLC | 6 | $102 |
| Astellas Pharma US Inc | 6 | $101 |
| Takeda Pharmaceuticals U.S.A., Inc. | 5 | $101 |
| Boehringer Ingelheim | 6 | $87 |
| Johnson & Johnson | 5 | $68 |
| Shire North American Group Inc | 5 | $63 |
| Edwards Lifesciences | 3 | $59 |
| Corcept Therapeutics | 2 | $34 |
| Genentech USA, Inc. | 2 | $31 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 1 | $23 |
| Inari Medical, Inc. | 1 | $21 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $19 |
| Teva Pharmaceuticals USA, Inc. | 1 | $17 |
| Upsher-smith Laboratories LLC | 1 | $16 |
| Phathom Pharmaceuticals, Inc. | 1 | $14 |
| E.r. Squibb & Sons, L.L.C. | 1 | $14 |
| Currax Pharmaceuticals LLC | 1 | $13 |
How this compares
$6,032 in reported general payments places this provider in the 85th percentile of 2,153 family medicine providers in South Carolina.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 195 | $196,777 |
| MounjaroTirzepatide | 100 | $152,666 |
| OzempicSemaglutide | 103 | $145,433 |
| JardianceEmpagliflozin | 95 | $70,929 |
| XareltoRivaroxaban | 53 | $44,832 |
| JanuviaSitagliptin Phosphate | 35 | $39,782 |
| Soliqua 100-33Insulin Glargine/Lixisenatide | 27 | $39,629 |
| FarxigaDapagliflozin Propanediol | 24 | $36,182 |
| TrulicityDulaglutide | 24 | $28,426 |
| EntrestoSacubitril/Valsartan | 38 | $26,057 |
| LinzessLinaclotide | 31 | $25,545 |
| Synjardy XrEmpagliflozin/Metformin Hcl | 23 | $25,498 |
| Repatha SureclickEvolocumab | 25 | $23,421 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 27 | $21,848 |
| MyrbetriqMirabegron | 25 | $20,894 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $432 | $196,777195 claims |
| Lilly USA, LLCMounjaro, Trulicity | $814 | $181,093124 claims |
| Novo NordiskOzempic | $1,017 | $145,433103 claims |
| Boehringer IngelheimJardiance, Synjardy Xr | $87 | $96,428118 claims |
| MerckJanuvia, Janumet Xr | $160 | $56,21550 claims |
| Johnson & JohnsonXarelto | $68 | $44,83253 claims |
| AstraZenecaFarxiga, Symbicort | $701 | $42,81342 claims |
| Sanofi-aventis U.S. LLCSoliqua 100-33 | $102 | $39,62927 claims |
| GSKTrelegy Ellipta, Breo Ellipta | $291 | $33,75456 claims |
| AbbVieLinzess, Savella | $513 | $31,43343 claims |
| NovartisEntresto | $203 | $26,05738 claims |
| Astellas Pharma US IncMyrbetriq | $101 | $20,89425 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 2,153 family medicine providers in South Carolina.
Other family medicine in Cayce
- Cayce TangemanGoose Creek$8.4M
- Jeremy AckermannMoncks Corner$7.6M
- Kelly MoralesNorth Charleston$6.5M
- William ByarsGreer$4.8M
- James FranklinGreenville$3.5M
- Stephen GrubbLittle River$3.4M
- Jeffrey HarrisGreenville$3.4M
- Shannon ConradN Charleston$3.3M
- Tom ChristensenLittle River$3.1M
- Edward NewtonCharleston$3M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.